<<<<<<< GBA HIGHLIGHTS >>>>>>>> 1> CYTK 2> DNA 3> MGM (and CZR) 4> RSI (Rush Street) 5> OCUL 6> LIFE 7> FOLD 8> BDSI What does it mean- six of the eight ideas are biotech?
I think it means exactly the opposite of what everybody is thinking. We are about to enter a speculative phase
I'll tell you the latest group think from these idiots. First you say "Stagflation" with a big stupid mock horror face.. as in Oh No Stagflation! Next you say smugly isn't stagflation stagnant growth? Well have you seen the most recent numbers? Goldman Sachs says 4% growth does that sound stagnant? No. It sounds decelerating Down from 5% which is down from 6% which is down from 8%.<-------- Like water in a bathtub. So what the Bankers are trying to sell us is: forget all the Fed help to the economy remember the liquidity we had to respect and all the buying and propping up by the Fed, forget all of that because that's how we get to 4% growth it's NOT NATURAL<----- Pull the wool over the eyes and just imagine it's straight up 4% that's not Stagnant thus we cannot be having Stagflation. It's a huge load of bunk.
I re found research on CYTK and posted it by accident on the wrong thread Ideas For Now but we had this puppy along time ago at a good price. Damn.
-- I admit there is some would of could of here.... aTyr Pharma produced some surprisingly strong results from recent trials of its lead drug candidate ATYR1923. ATYR1923 is indicated for Pulmonary Sarcoidosis - a ~200k patient population - but could address the $2-$3bn wider ILD market. The company's pipeline is based around founder Paul Schimmel, of the Scripps Institute, and is based around the biology of the extracellular activity of histidyl-tRNA synthetase. It is unique and appears to be quite promising - the company has built an intellectual property portfolio covering >300 protein compositions targeting inflammation, fibrosis and oncology.
That was yesterday silly. Did you do your homework? Hey, this eye medicine stuff reminded me to check in on an old friend.... ALDX They did an Oppenheimer presentation last month and the stock went up 6 days in a row on a pick-up in volume. It hit $9 and pulled back. It's held this $8.50 level since. ALDX is going into the GBA-VZ portfolio at $8.50 IWM is the Russell 2000 btw in case you didn't look. That's not the right stock really for the short side of the portfolio, that was more of a long term call. A 15% move in it would be significant really, in the bigger picture of things; ie a true market "correction" across the board. So it's out. I'll find a good short to replace DPZ. ALDX Stoney!!!!!!! It's a sleeper.
SQM price target raised to $70 from $62 at Citi 08:47 SQM Citi analyst P.J. Juvekar raised the firm's price target on SQM (SQM) to $70 from $62 and keeps a Buy rating on the shares. The lithium sector continues to benefit from tight fundamentals as demand is strong from electric vehicles and supply struggles to keep pace, Juvekar tells investors in a research note. The analyst says Albemarle (ALB) is his top pick in lithium, followed by SQM and Livent (LTHM).